DVD

Psychopharmacology for Mental Health Professionals



Most clients with DSM-5® diagnoses are being treated with a combination of psychological and pharmacological treatments. Newer drugs are being developed to treat mental disorders based on a better understanding of neurobiological contributions to mental disorders and the latest pharmacological research. To provide appropriate services, you are expected to have a thorough understanding of these common and complex issues. As a mental health professional, keeping up-to-date is essential.

This seminar will update and increase your knowledge of:

  • Neurobiological underpinnings of major DSM-5® diagnoses
  • Effects and side effects of drugs used to treat these diagnoses
  • Responsibilities of the non-prescribing therapist to clients taking psychiatric medication

Specifics of the pharmacological treatment and drugs of choice for Depressive, Bipolar, Schizophrenia Spectrum, Anxiety, OCD, Sleep-Wake, ADHD and Neurocognitive disorders will be presented. Unique to this seminar is information on the common types of psychotherapeutic drugs and other drugs that are abused, and methods for prevention and early detection. Throughout the day, representative case studies will generate discussion and examination of the latest drug treatment for DSM-5® disorders. You will leave this program with knowledge and confidence regarding effective and safe application of pharmacological drugs.


Details

Product Details
Average Rating:
   4.3
Speakers:
Alan S. Bloom, Ph.D. |  Margaret L. Bloom, Ph.D.
Duration:
6 Hours 04 Minutes
Copyright:
Sep 14, 2021
Publisher:
PESI Inc.
Product Code:
RNV045905
Media Type:
DVD - Also available: Digital Recordings

CPD


CPD

This online program is worth 6.25 hours CPD.



Handouts

Speakers

Alan S. Bloom, Ph.D. Related seminars and products


Alan Bloom, Ph.D., is a professor of pharmacology and toxicology at the Medical College of Wisconsin. He earned a joint Ph.D. in psychology and pharmacology and consults regularly with psychiatrists and attorneys in drug abuse and other pharmacology related cases. Dr. Bloom has conducted extensive research on the impact of drugs of abuse (marijuana, cocaine, etc.) on the brain through use of functional magnetic resonance imaging (fMRI). His studies have been funded by the NIH and other national organizations and reported in an extensive number of publications and presentations. Dr. Bloom has served on the NIDA center grant review panel and is an appointed member of the Controlled Substance Board of the State of Wisconsin. He is a strong and experienced presenter providing lively, information-packed seminars.

Speaker Disclosures:

Speaker Disclosures: Speaker Disclosure: Financial: Alan Bloom is a Professor of Pharmacology and Toxicology at the Medical College of Wisconsin. He receives a speaking honorarium from PESI, Inc.

Non-financial: Alan Bloom is the vice-chair for the State of Wisconsin Controlled Substances Board.


Margaret L. Bloom, Ph.D.'s Profile

Margaret L. Bloom, Ph.D. Related seminars and products


Margaret (Peggy) L. Bloom, Ph.D., Professor Emerita, Counselor Education and Counseling Psychology, Marquette University, Milwaukee, Wisconsin is a licensed psychologist and NCC certified counselor. Dr. Bloom is nationally recognized for her knowledge and expertise in assessment, DSM diagnosis and counselor education. She is past chair and member of the board of directors of the Center for Credentialing & Education (NBCC), an elected fellow of the American Psychological Association (APA) and past-president of the Association for Counselor Education and Supervision (ACES). Beginning her career as a psychiatric nurse and earning graduate degrees in nursing, counseling, and a Ph.D. in counseling psychology, Peggy brings a unique interdisciplinary perspective to each seminar. She has published numerous journal articles and presented professional education seminars across the world on assessment, diagnosis and counselor education. In addition to her university positions, she maintained a private therapy practice for many years.


Speaker Disclosures:
Financial: Margaret Bloom is a Professor of Counselor Education and Counseling Psychology at Marquette University. She receives a speaking honorarium from PESI, Inc.
Non-financial: Margaret Bloom has no relevant non-financial relationship to disclose.


Additional Info

Program Information

Access for Self-Study (Non-Interactive)

Access never expires for this product.


Questions?

Visit our FAQ page at www.pesi.com/faq or contact us at www.pesi.com/info


Objectives

  1. Communicate the neurotransmitter systems and neuroanatomy underlying the biological basis for mental disorders and pharmacotherapy.
  2. Evaluate the role of mental health professionals who treat clients receiving both psychotherapeutic medications and psychotherapy.
  3. Analyze the major classes of drugs used to treat mental disorders and which mental disorders are appropriately treated with each class of drugs.
  4. Analyze the effects and side effects of various psychotropic medications, including antipsychotics, antidepressants, benzodiazepines and anticonvulsants.
  5. Determine the abuse liability of drugs used in the treatment of anxiety, insomnia, pain and ADHD.
  6. Implement methods for prevention and early identification of prescription drug abuse among clients.

Outline

Psychopharmacological Foundations
Core Pharmacological Principles
  • Brain structures & circuits involved in:
    • Emotional regulation
    • Executive function & inhibitory control
    • Reward & pleasure
    • Learning & memory
  • Receptors and neurotransmitters important in the actions of psychopharmacological agents
    • Biogenic amines
    • Excitatory & inhibitory neurotransmitters
    • Endorphins & endocannabinoids
Your role in combined psychological & pharmacological treatments
  • Collaboration & communication with prescribing professionals
  • Managing the combined treatments
    • Referrals for medication
    • Client psycho-education
    • Monitoring drug effects & side effects
    • Promoting adherence to combined treatments
Drugs Used in the Treatment of DSM-5® Mental Disorders

Depressive Disorders

  • Neurobiology of depression
  • Drugs used to treat depressive disorders
    • Selective Serotonin Reuptake inhibitors (SSRIs)
      • Effects, side effects and cautions
      • Suicide risk & discontinuation syndrome
      • Serotonin syndrome
  • Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
    • Effects, side effects, and cautions
  • Atypical antidepressant agents
    • Effects, side effects, and cautions
  • Tricyclic antidepressants (TCAs)
    • Effects, side effects, and cautions
    • Why were newer drugs needed?
  • MAO inhibitors
    • Effects, side effects, and cautions
  • Choosing an antidepressant
  • What if first-line antidepressants do not work?
    • Augmentation with antipsychotics
  • What about herbs like St. John’s Wort?
Schizophrenia Spectrum Disorders
  • Biological theories of schizophrenia
  • ”Typical” & “atypical” antipsychotic drugs
    • Effects, side effects & cautions – similarities & differences
  • Latest evidence-based comparisons
  • Drugs for treatment-resistant schizophrenia
  • Other uses of antipsychotic drugs
Bipolar Disorders
  • Biological theories for bipolar disorders
  • Drugs used to treat bipolar disorders
    • A prototype agent – lithium
      • Effects, side effects & cautions
    • Anticonvulsants
      • Effects, side effects & cautions
    • Antipsychotics – approved agents
    • Combination drug therapy
Anxiety, Obsessive-Compulsive & Sleep-Wake Disorders
  • The neurobiology of anxiety-related disorders
  • The structure of sleep
  • Drugs used in the treatment of anxiety & insomnia
    • Benzodiazepines & Benzodiazepine-like drugs
    • Misuse of these drugs in treatment
    • SSRI’s & other drugs used to treat anxiety
Attention-Deficit/Hyperactivity Disorder & Neurocognitive Disorders (Dementia)
  • ADHD
    • Psycho-stimulants
      • Effects, side effects & cautions
    • Alpha-Adrenergic Agonists
  • Major neurocognitive disorders
    • Drugs used in the treatment of cognitive impairment
    • Future treatments
Prescription Drug Abuse
  • Mental disorders & risk of comorbid prescription drug abuse
  • Classes of drugs that are frequently abused
    • Stimulants
    • Sedative-hypnotics
    • Opiates
  • Strategies for the prevention & early identification of prescription drug abuse
Limitations of the Research and Potential Risks

Target Audience

  • Counselors
  • Psychotherapists
  • Psychologists
  • Social Workers
  • Nurse Practitioners
  • Case Managers
  • Marriage & Family Therapists
  • Addiction Counselors
  • Nurses
  • Physicians
  • Clinical Nurse Specialists
  • Pharmacists
  • School Psychologists
  • Occupational Therapists
  • Occupational Therapy Assistants
  • Other Mental Health Professionals

Reviews

5
4
3
2
1

Overall:      4.3

Total Reviews: 12

Comments

Sarah W

"great program. SO informational!"

Jacqueline T

"Super informative course!"

ELISE K

"the whole experience was excellent"

LARA W

"Both the presenter and the quality of the information were fantastic."

Leslie S

"Great seminar, thank you!"

Natalie B

"Excellent course and presentation."

Satisfaction Guarantee
Your satisfaction is our goal and our guarantee. Concerns should be addressed to info@pesi.co.uk or call 01235847393.

Please wait ...

Back to Top